Info
atezolizumab
- Atezolizumab (Tecentriq)
- Mechanism: Binds to PD-L1
- Dosing:
- 840 mg every 2 wks,
- 1,200 mg IV every 3 wks,
- or 1,680 mg every 4 wks; hold for hepatic tox,
- ↑ Scr,
- & immune-mediated AEs
- PK/PD: T1/2 ∼27 d
- AEs:
- Immune-mediated tox,
- lymphocytopenia,
- GI tox,
- rash,
- infusion rxn,
- metabolic abnormalities,
- pneumonitis,
- ↑ liver enzymes,
- endocrinopathies
- DDI: No known pathways of metabolism
- Clinical pearls:
- Tx immune-related tox w/ steroids (prednisone 1-2 mg/kg/d),
- WARN: can increase complications post allogeneic HSCT